Published in J Cancer on August 22, 2015
Folate deficient tumor microenvironment promotes epithelial-to-mesenchymal transition and cancer stem-like phenotypes. Oncotarget (2016) 0.81
Notch Signaling Activation in Cervical Cancer Cells Induces Cell Growth Arrest with the Involvement of the Nuclear Receptor NR4A2. J Cancer (2016) 0.79
Assessment of Interactions between Cisplatin and Two Histone Deacetylase Inhibitors in MCF7, T47D and MDA-MB-231 Human Breast Cancer Cell Lines - An Isobolographic Analysis. PLoS One (2015) 0.78
Histone Deacetylase Inhibitor Phenylbutyrate Exaggerates Heart Failure in Pressure Overloaded Mice independently of HDAC inhibition. Sci Rep (2016) 0.75
NOTCH receptors in gastric and other gastrointestinal cancers: oncogenes or tumor suppressors? Mol Cancer (2016) 0.75
Activated Notch signaling augments cell growth in hepatocellular carcinoma via up-regulating the nuclear receptor NR4A2. Oncotarget (2017) 0.75
Cancer statistics, 2014. CA Cancer J Clin (2014) 72.81
Hepatocellular carcinoma. N Engl J Med (2011) 19.40
Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology (2012) 10.00
Epidemiology of hepatocellular carcinoma: consider the population. J Clin Gastroenterol (2013) 3.12
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. J Hepatol (2012) 3.04
Valproic acid activates notch-1 signaling and regulates the neuroendocrine phenotype in carcinoid cancer cells. Oncologist (2007) 1.96
Notch1 signaling inhibits growth of human hepatocellular carcinoma through induction of cell cycle arrest and apoptosis. Cancer Res (2003) 1.92
Tumor suppressor role of Notch-1 signaling in neuroendocrine tumors. Oncologist (2007) 1.78
Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors. Cancer Treat Rev (2008) 1.74
Notch signaling inhibits hepatocellular carcinoma following inactivation of the RB pathway. J Exp Med (2011) 1.74
Notch signaling is activated in human hepatocellular carcinoma and induces tumor formation in mice. Gastroenterology (2012) 1.71
Constitutive Notch2 signaling induces hepatic tumors in mice. Hepatology (2013) 1.65
Histone deacetylase inhibitors in cancer treatment. Anticancer Drugs (2002) 1.62
Notch signaling: emerging molecular targets for cancer therapy. Biochem Pharmacol (2010) 1.54
Emerging roles of Notch signaling in liver disease. Hepatology (2014) 1.39
Selective class I histone deacetylase inhibition suppresses hypoxia-induced cardiopulmonary remodeling through an antiproliferative mechanism. Circ Res (2012) 1.37
Emerging signaling pathways in hepatocellular carcinoma. Liver Cancer (2012) 1.32
Liver cancer in 2013: Mutational landscape of HCC--the end of the beginning. Nat Rev Clin Oncol (2014) 1.22
Aberrant Notch3 and Notch4 expression in human hepatocellular carcinoma. Liver Int (2007) 1.15
Selective ablation of Notch3 in HCC enhances doxorubicin's death promoting effect by a p53 dependent mechanism. J Hepatol (2009) 1.14
A pilot phase II study of valproic acid for treatment of low-grade neuroendocrine carcinoma. Oncologist (2011) 1.05
Down-regulation of Notch1 signaling inhibits tumor growth in human hepatocellular carcinoma. Am J Transl Res (2009) 1.04
Notch1 and Notch4 are markers for poor prognosis of hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int (2013) 1.02
Resveratrol as a pan-HDAC inhibitor alters the acetylation status of histone [corrected] proteins in human-derived hepatoblastoma cells. PLoS One (2013) 1.01
Valproic acid induces Notch1 signaling in small cell lung cancer cells. J Surg Res (2008) 0.99
Inhibitory effects of the HDAC inhibitor valproic acid on prostate cancer growth are enhanced by simultaneous application of the mTOR inhibitor RAD001. Life Sci (2010) 0.97
Notch signaling and new therapeutic options in liver disease. J Hepatol (2013) 0.96
Somatostatin receptor-targeted anti-cancer therapy. Curr Drug Deliv (2011) 0.93
Notch1-mediated tumor suppression in cervical cancer with the involvement of SST signaling and its application in enhanced SSTR-targeted therapeutics. Oncologist (2012) 0.92
Notch signalling beyond liver development: emerging concepts in liver repair and oncogenesis. Clin Res Hepatol Gastroenterol (2013) 0.92
Notch3 inhibition enhances sorafenib cytotoxic efficacy by promoting GSK3b phosphorylation and p21 down-regulation in hepatocellular carcinoma. Oncotarget (2013) 0.91
Valproic acid suppresses cervical cancer tumor progression possibly via activating Notch1 signaling and enhances receptor-targeted cancer chemotherapeutic via activating somatostatin receptor type II. Arch Gynecol Obstet (2013) 0.89
The roles of transforming growth factor-β, Wnt, Notch and hypoxia on liver progenitor cells in primary liver tumours (Review). Int J Oncol (2014) 0.88
Acyclic retinoid synergises with valproic acid to inhibit growth in human hepatocellular carcinoma cells. Cancer Lett (2009) 0.87
HDAC2 provides a critical support to malignant progression of hepatocellular carcinoma through feedback control of mTORC1 and AKT. Cancer Res (2014) 0.86
Hepatitis B virus X protein promotes the growth of hepatocellular carcinoma by modulation of the Notch signaling pathway. Oncol Rep (2012) 0.85
Aberrant expression of Notch3 predicts poor survival for hepatocellular carcinomas. Biosci Trends (2013) 0.84
Valproic acid overcomes transforming growth factor-β-mediated sorafenib resistance in hepatocellular carcinoma. Int J Clin Exp Pathol (2014) 0.82
Targeted chemotherapy using a cytotoxic somatostatin conjugate to inhibit tumor growth and metastasis in nude mice. Clin Med Oncol (2008) 0.81
Synergistically killing activity of aspirin and histone deacetylase inhibitor valproic acid (VPA) on hepatocellular cancer cells. Biochem Biophys Res Commun (2013) 0.81
Valproic acid inhibits human hepatocellular cancer cells growth in vitro and in vivo. J Exp Ther Oncol (2011) 0.81
Notch1 activation contributes to tumor cell growth and proliferation in human hepatocellular carcinoma HepG2 and SMMC7721 cells. Int J Oncol (2012) 0.79
Is Notch Signaling a Specific Target in Hepatocellular Carcinoma? Anticancer Agents Med Chem (2015) 0.78